GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » ROE %
中文

RadNet (RadNet) ROE % : -1.19% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is RadNet ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. RadNet's annualized net income for the quarter that ended in Dec. 2023 was $-7 Mil. RadNet's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $625 Mil. Therefore, RadNet's annualized ROE % for the quarter that ended in Dec. 2023 was -1.19%.

The historical rank and industry rank for RadNet's ROE % or its related term are showing as below:

RDNT' s ROE % Range Over the Past 10 Years
Min: -9.35   Med: 11.56   Max: 52.1
Current: 0.61

During the past 13 years, RadNet's highest ROE % was 52.10%. The lowest was -9.35%. And the median was 11.56%.

RDNT's ROE % is ranked better than
55.96% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.13 vs RDNT: 0.61

RadNet ROE % Historical Data

The historical data trend for RadNet's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RadNet ROE % Chart

RadNet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.58 -9.35 12.53 3.79 0.63

RadNet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.16 -25.43 7.27 11.58 -1.19

Competitive Comparison of RadNet's ROE %

For the Diagnostics & Research subindustry, RadNet's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RadNet's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's ROE % distribution charts can be found below:

* The bar in red indicates where RadNet's ROE % falls into.



RadNet ROE % Calculation

RadNet's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=3.044/( (332.995+630.695)/ 2 )
=3.044/481.845
=0.63 %

RadNet's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-7.44/( (618.901+630.695)/ 2 )
=-7.44/624.798
=-1.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


RadNet  (NAS:RDNT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7.44/624.798
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.44 / 1681.532)*(1681.532 / 2689.249)*(2689.249 / 624.798)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.44 %*0.6253*4.3042
=ROA %*Equity Multiplier
=-0.28 %*4.3042
=-1.19 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7.44/624.798
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7.44 / 26.912) * (26.912 / 124.42) * (124.42 / 1681.532) * (1681.532 / 2689.249) * (2689.249 / 624.798)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -0.2765 * 0.2163 * 7.4 % * 0.6253 * 4.3042
=-1.19 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


RadNet ROE % Related Terms

Thank you for viewing the detailed overview of RadNet's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


RadNet (RadNet) Business Description

Traded in Other Exchanges
Address
1510 Cotner Avenue, Los Angeles, CA, USA, 90025
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
Executives
Michael N Murdock officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Christine Nayoma Gordon director 3081 PANAMA AVE., CARMICHAEL CA 95608
Gregory Sorensen director, officer: EVP Chief Science Officer C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Norman R Hames director, officer: Vice President
Stephen M Forthuber officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
Ruth Louisa Villigerwilson director, officer: Senior Vice President 3700 WALNUT AVENUE, LONG BEACH CA 90801
David L Swartz director 1510 COTNER AVENUE, LOS ANGELES CA 90025
Gregory E. Spurlock director 4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
John V Crues director 1510 COTNER AVE, LOS ANGELES CA 90025
Lawrence L Levitt director 2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Ranjan Jayanathan officer: Chief Information Officer 13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Laura Pastre Jacobs director 10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064
Karen B. Kaplan Survivor's Trust other: Indirect owner 10776 WILSHIRE BLVD/, LOS ANGELES CA 90024-6447
David Jeffrey Katz officer: EVP and General Counsel 1510 COTNER AVE, LOS ANGELES CA 90025
Sherman Michael L Md director